Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Inno

Showing results (71-80 of 101) with videos related to

Pageof 11
Sort By:
International Journal of Molecular Sciences|September 27, 2025
Long-Term Cardiovascular Toxicity of Immunotherapy: Too Important to IgnoreAndrea Camerini, Alessandro Inno, Maria Laura Canale, et al.
Journal of Cardiovascular Pharmacology|September 26, 2025
Time to Combinatorial Regimens: SGLT2i and PCSK9i in High-Risk Cardio-Oncology PatientsVincenzo Quagliariello, Massimiliano Berretta, Irma Bisceglia, et al.
Plos One|May 26, 2016
Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC StudyStefania Gori, Alessandro Inno, Valentina Rossi, et al.
Oncotarget|January 23, 2016
Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNAMarzia Del Re, Marcello Tiseo, Paola Bordi, et al.
Cardio-Oncology (London, England)|June 19, 2026
Environmental endocrine disruptors in cardio-oncology: emerging modifiers of cardiovascular vulnerability in patients with cancerVincenzo Quagliariello, Massimiliano Berretta, Giuseppe D'Aiuto, et al.
Clinical Breast Cancer|June 18, 2019
The HERBA Study: A Retrospective Multi-Institutional Italian Study on Patients With Brain Metastases From HER2-Positive Breast CancerStefania Gori, Fabio Puglisi, Stefano Moroso, et al.
Journal of Cardiovascular Pharmacology|January 27, 2026
Evidence of Cardiotoxic Immune Activation by Triple Immune Checkpoint Blockade: A Translational Alert for Clinical Surveillance in cancer patientsVincenzo Quagliariello, Margherita Passariello, Martina Belardo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 29, 2018
PD-L1 Expression Heterogeneity in Non-Small Cell Lung Cancer: Defining Criteria for Harmonization between Biopsy Specimens and Whole SectionsEnrico Munari, Giuseppe Zamboni, Gianluigi Lunardi, et al.
Giornale Italiano Di Cardiologia (2006)|September 29, 2024
[Atherosclerosis, cancer and immune checkpoint inhibitors]Maria Laura Canale, Alessandra Greco, Alessandro Inno, et al.
European Journal of Cancer (Oxford, England : 1990)|April 10, 2022
Clinical profile and mortality of Sars-Cov-2 infection in cancer patients across two pandemic time periods (Feb 2020-Sep 2020; Sep 2020-May 2021) in the Veneto Oncology Network: The ROVID studyMaria V Dieci, Giuseppe Azzarello, Vittorina Zagonel, et al.
Pageof 11

Showing results (71-80 of 101) with videos related to

Sort By:
Pageof 11
International Journal of Molecular Sciences|September 27, 2025
Long-Term Cardiovascular Toxicity of Immunotherapy: Too Important to IgnoreAndrea Camerini, Alessandro Inno, Maria Laura Canale, et al.
Journal of Cardiovascular Pharmacology|September 26, 2025
Time to Combinatorial Regimens: SGLT2i and PCSK9i in High-Risk Cardio-Oncology PatientsVincenzo Quagliariello, Massimiliano Berretta, Irma Bisceglia, et al.
Plos One|May 26, 2016
Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC StudyStefania Gori, Alessandro Inno, Valentina Rossi, et al.
Oncotarget|January 23, 2016
Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNAMarzia Del Re, Marcello Tiseo, Paola Bordi, et al.
Cardio-Oncology (London, England)|June 19, 2026
Environmental endocrine disruptors in cardio-oncology: emerging modifiers of cardiovascular vulnerability in patients with cancerVincenzo Quagliariello, Massimiliano Berretta, Giuseppe D'Aiuto, et al.
Clinical Breast Cancer|June 18, 2019
The HERBA Study: A Retrospective Multi-Institutional Italian Study on Patients With Brain Metastases From HER2-Positive Breast CancerStefania Gori, Fabio Puglisi, Stefano Moroso, et al.
Journal of Cardiovascular Pharmacology|January 27, 2026
Evidence of Cardiotoxic Immune Activation by Triple Immune Checkpoint Blockade: A Translational Alert for Clinical Surveillance in cancer patientsVincenzo Quagliariello, Margherita Passariello, Martina Belardo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 29, 2018
PD-L1 Expression Heterogeneity in Non-Small Cell Lung Cancer: Defining Criteria for Harmonization between Biopsy Specimens and Whole SectionsEnrico Munari, Giuseppe Zamboni, Gianluigi Lunardi, et al.
Giornale Italiano Di Cardiologia (2006)|September 29, 2024
[Atherosclerosis, cancer and immune checkpoint inhibitors]Maria Laura Canale, Alessandra Greco, Alessandro Inno, et al.
European Journal of Cancer (Oxford, England : 1990)|April 10, 2022
Clinical profile and mortality of Sars-Cov-2 infection in cancer patients across two pandemic time periods (Feb 2020-Sep 2020; Sep 2020-May 2021) in the Veneto Oncology Network: The ROVID studyMaria V Dieci, Giuseppe Azzarello, Vittorina Zagonel, et al.
Pageof 11